Astellas Pharma Inc: Candidemia trials

The registry lists 10 Candidemia studies with Astellas Pharma Inc as lead sponsor. 0 are open to participants now and 2 have results posted.

Phase 1 2Phase 2 1Phase 3 5Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal CandidiasisTerminatedNCT00815516Phase 3Results posted
• Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida InfectionsCompletedNCT00413218Phase 3Results posted
• Non-interventional Study for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania - ERADICATE StudyCompletedNCT03174457
• A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or CandidemiaTerminatedNCT01982071Phase 4
• Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the DrugCompletedNCT00608335Phase 1
• Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the DrugCompletedNCT00607763Phase 1
• Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and CandidemiaCompletedNCT00189709Phase 3
• Micafungin Versus AmBisome in Invasive Candidiasis and CandidemiaCompletedNCT00106288Phase 3
• Study of Micafungin in Patients With Invasive Candidiasis or CandidemiaCompletedNCT00105144Phase 3
• Study of FK463 in the Treatment of Candidemia or Invasive CandidiasisCompletedNCT00036179Phase 2